• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

(+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.

作者信息

Grandas Perez F J, Jenner P G, Nomoto M, Stahl S, Quinn N P, Parkes J D, Critchley P, Marsden C D

出版信息

Lancet. 1986 Apr 19;1(8486):906. doi: 10.1016/s0140-6736(86)91004-4.

DOI:10.1016/s0140-6736(86)91004-4
PMID:2870368
Abstract
摘要

相似文献

1
(+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.（+）-4-丙基-9-羟基萘并恶嗪在帕金森病中的应用
Lancet. 1986 Apr 19;1(8486):906. doi: 10.1016/s0140-6736(86)91004-4.
2
Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease.
Clin Neuropharmacol. 1986;9(5):440-7. doi: 10.1097/00002826-198610000-00004.
3
The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.（+）-4-丙基-9-羟基萘恶嗪作为帕金森病辅助治疗的疗效。
J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):732-5. doi: 10.1136/jnnp.52.6.732.
4
Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.帕金森病中经鼻胃管和静脉输注（+）-4-丙基-9-羟基萘恶嗪（PHNO）
J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):102-5. doi: 10.1136/jnnp.53.2.102.
5
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.缓释（+）-PHNO [MK-458（羟丙基甲基纤维素）]治疗帕金森病：对作为长效制剂给予的选择性D2受体激动剂产生耐受性的证据。
Mov Disord. 1990;5(4):298-303. doi: 10.1002/mds.870050407.
6
One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease.培高利特作为息宁辅助药物治疗帕金森病的一年试验。
Adv Neurol. 1984;40:537-9.
7
Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.帕金森病控释型MK-458（PHNO）单药治疗：双盲研究及与卡比多巴/左旋多巴的比较
Clin Neuropharmacol. 1991 Jun;14(3):214-27. doi: 10.1097/00002826-199106000-00004.
8
Augmentation of artistic productivity in Parkinson's disease.帕金森病患者艺术创造力的增强。
Mov Disord. 2006 Feb;21(2):285-6. doi: 10.1002/mds.20758.
9
The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.经皮给药（+）-4-丙基-9-羟基萘并恶嗪（+PHNO）的抗帕金森病作用及药代动力学：初步结果
Mov Disord. 1989;4(2):129-38. doi: 10.1002/mds.870040204.
10
New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.帕金森病多巴胺能治疗的新策略：控释制剂的应用。英国伦敦，1989年4月28日和29日。会议论文集。
Neurology. 1989 Nov;39(11 Suppl 2):1-106.

引用本文的文献

1
Binding of (+)PHNO and other D2-dopamine agonists to D1-dopamine receptors labelled by [3H]SCH 23390.（+）PHNO及其他D2-多巴胺激动剂与用[3H]SCH 23390标记的D1-多巴胺受体的结合。
J Neural Transm. 1987;69(1-2):147-51. doi: 10.1007/BF01244105.
2
Endocrine and neurochemical effects of (+)-PHNO, a dopamine D2 agonist.
J Neural Transm. 1989;75(1):11-20. doi: 10.1007/BF01250640.
3
Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）处理的松鼠猴中左旋多巴诱发的运动障碍的特征
Psychopharmacology (Berl). 1990;102(1):21-7. doi: 10.1007/BF02245739.
4
Failure of oral administration of single rising doses of bromocriptine to produce acute anti-Parkinsonian effects.单次递增剂量口服溴隐亭未能产生急性抗帕金森病效应。
J Neurol Neurosurg Psychiatry. 1991 Feb;54(2):186-7. doi: 10.1136/jnnp.54.2.186.
5
(+)-PHNO: a new anti-parkinsonian agent which does not induce chorea in MPTP-treated squirrel monkeys.（+）-PHNO：一种新型抗帕金森病药物，在经MPTP处理的松鼠猴中不会诱发舞蹈症。
J Neurol Neurosurg Psychiatry. 1990 Jul;53(7):622-3. doi: 10.1136/jnnp.53.7.622.